Clinical Trials Logo
  1. Home
  2. Ocular Melanoma
  3. NCT03172299
  4. Details
NCT03172299 Clinical Trial

Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma

Ocular Melanoma Clinical Trial

— PROTECT  

Official title:
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal Melanoma

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03172299
Other study ID # 15-API-01
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 8, 2017
Est. completion date December 2026

Study information
Verified date June 2023
Source Centre Hospitalier Universitaire de Nice
Contact Stéphanie BAILLIF, Pr
Phone 492038025
Email baillif.s@chu-nice.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The reference treatment of ocular melanoma is a conservative treatment by proton therapy. Its goal is to treat the tumor while preserving the eyeball and visual acuity. However, ablation of the eyeball is sometimes necessary after proton therapy in the case of neovascular glaucoma. This complication occurs in 7 to 47% of cases (depending on the size of the tumor) and is associated with hypersecretion of Vascular Endothelial Growth Factor (VEGF) related to necrotic and inflammatory tumor tissue after proton therapy or ischemic retina. The intravitreal injections of anti-VEGF are used in the treatment of neovascular radicular glaucoma without avoiding enucleation in all cases. The investigators propose to study the prevention of neovascular glaucoma by intravitreal prophylactic administration of anti-VEGF.

Recruitment information / eligibility
Status Recruiting
Enrollment 56
Est. completion date December 2026
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Choroid melanoma more than 7mm thick and / or over basal diameter of 15mm treated by proton therapy Exclusion Criteria: - Iris melanoma - Melanoma immediately metastatic - Pregnant or breastfeeding women - Known hypersensitivity to aflibercept (anti-VEGF selected)

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Aflibercept Injection
Intravitreal injection of aflibercept 40mg/mL will be done on patients. The injections will be performed on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, injections will be performed every 3 months for a period of 21 months.
• False injection
A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.

Locations
Country Name City State
France CHU de Nice Nice

Sponsors (1)
Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Occurrence of neovascular glaucoma Occurrence of neovascular glaucoma after radiation-induced proton therapy. Clinical diagnosis (examination at the slit lamp) at 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04364230 - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) Phase 1/Phase 2
Completed NCT01200238 - STA-9090(Ganetespib) in Metastatic Ocular Melanoma Phase 2
Completed NCT02858869 - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Phase 1
Completed NCT01355120 - THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Phase 2
Recruiting NCT05524935 - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Phase 2
Recruiting NCT05628883 - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Phase 1
Active, not recruiting NCT05187884 - Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma Phase 2
Recruiting NCT02909517 - The Role of Inflammation in Ocular Tumours
Withdrawn NCT00621439 - Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye N/A
Terminated NCT00346372 - Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
Not yet recruiting NCT06432660 - Eye Plaque Brachytherapy for Ocular Melanoma
Completed NCT01893099 - Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma Phase 1
Completed NCT00351728 - Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone N/A
Active, not recruiting NCT03528408 - Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Phase 2
Completed NCT03052127 - Study in Subjects With Small Primary Choroidal Melanoma Phase 1/Phase 2
Withdrawn NCT01930968 - Definity for Ultrasound of Intraocular Tumors
Recruiting NCT00168870 - Study of Metastatic Ocular Melanoma Phase 2
Completed NCT02519322 - Neoadjuvant and Adjuvant Checkpoint Blockade Phase 2
Recruiting NCT06007690 - A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma Phase 3
Active, not recruiting NCT04417530 - Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Phase 2